SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports that Nvidias board is investigating CEO Jensen Huangs relationship with a businesswoman alleged by U.S. intelligence to be a Chinese spy have focused attention on governance, security and leadership risks. Traders are divided between viewing the controversy as an overblown personal matter and buying the selloff, and worrying about possible information exposure or Huangs departure.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A quarterly revenue miss and signs of uneven ANKTIVA sales have fueled a sharp selloff and concerns about commercial adoption, cash burn, and possible dilution. Bulls counter that ANKTIVA plus BCG met the primary endpoint in a BCG-naive bladder cancer trial, but traders are weighing that clinical progress against the weaker sales report.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly report showed strong BRIUMVI-driven revenue growth and a raised full-year outlook, prompting a largely bullish reaction. Traders also point to short-interest-driven volatility and the upcoming Phase 3 readout for subcutaneous BRIUMVI, while buyout talk remains speculative.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks upcoming quarterly earnings are driving attention after a prolonged share-price decline, with traders bracing for a potentially sharp move. Bulls hope for a positive report and point to high short interest and the return of co-founder Dave Pickles as possible support, while bears expect weak results or guidance and another selloff.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Stronger-than-expected quarterly results and a raised 2026 earnings outlook are driving attention, with traders linking the outlook to capacity pricing and demand for reliable power from AI data centers. The reaction is broadly bullish, though some traders question why the shares are not moving more sharply.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Debate over DefenCaths post-TDAPA reimbursement is driving attention after DaVita warned that payments could decline under quarterly recalculations, fueling a sharp selloff. Bulls counter that the first-quarter rate came in above expectations and DaVitas outlook was preliminary, while investors await clearer signals on utilization and Medicare Advantage uptake.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Mercks positive Phase 2b hidradenitis suppurativa data has renewed debate about competition for MoonLakes sonelokimab, while bullish traders emphasize that MLTXs program is further advanced and its BLA has been submitted. The upcoming FDA decision on whether to accept the application is a key milestone, but concerns about competition and MoonLakes ability to commercialize independently temper optimism.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs steep decline amid a broader crypto selloff is dominating discussion, with traders citing weakness alongside Bitcoin and uncertainty over U.S. crypto regulation, including the stalled Clarity Act. The community is split between buying the dip and expecting further losses, while some also question XRPs lack of price response to Ripple-related developments.

NRG Energy, Inc. engages in the production, sale, and distribution of energy and energy services. It operates through the following segments: Texas, East, West/Services/Other, Vivint Smart Home, and Corporate Activities. The Texas segment includes all activities related to customer, plant and market operations in Texas, other than Cottonwood. The East segment engages in all activities related to customer, plant and market operations in the East. The West/Services/Other segment is focused on all activities related to customer, plant and market operations in the West and Canada, and activities related to the Cottonwood facility and other investments. The Vivint Smart Home segment is a smart home platform that provides customers with technology, products and services to create a smarter, greener, safer home. The company was founded in 1989 and is headquartered in Houston, TX.

NRG Energy Inc.

NRG is drawing attention after strong quarterly results and an announced sale of six generation assets to LS Power; traders are reacting positively to the earnings and cash from the divestiture, while some question the loss of future earnings from the plants.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of expected Q4 2026 Phase 3 APPROACH topline results for HLP003, its investigational depression treatment. Bulls emphasize its adjunctive trial design and potential for shorter clinic visits, while skeptics point to binary trial risk, possible dilution, and competition in psychedelic therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


keonhacai1jpnet

Kèo Nhà Cái